Blockchain In Clinical Trials Market Size, Share, Opportunities, And Trends By Type Of Blockchain (Public Blockchain, Private Blockchain, Consortium Blockchain, Hybrid Blockchain), By Application (Patient Data Management, Supply Chain Management, Clinical Data Exchange And Sharing, Clinical Trial Recordkeeping, Informed Consent Management, Drug Traceability And Authenticity, Others), By End-User (Pharmaceutical Companies, Contract Research Organizations (Cros), Research Institutes And Academic Centers, Healthcare Providers, Others), And By Geography - Forecasts From 2025 To 2030

Blockchain In Clinical Trials Market Size:

Blockchain In Clinical Trials Market is projected to expand at a 22.79% CAGR, attaining USD 428.191 million by 2030 from USD 153.392 million in 2025.

Blockchain In Clinical Trials Market Key Highlights:

• Increasing data transparency by enabling real-time, tamper-proof sharing across clinical trial stakeholders.
• Enhancing trust and compliance by securing participant consent and reducing data manipulation risks.
• Streamlining trial processes by automating data management, verification, and access control systems.
• Boosting patient engagement by allowing direct, secure data sharing and informed participation in trials.

Blockchain In Clinical Trials Market Trends:

In the healthcare and pharmaceutical industries, the blockchain in clinical trials market has emerged as a transformational force. This novel strategy promises to improve openness, security, and efficiency in the clinical trial process by leveraging blockchain technology's decentralised and irreversible nature. Blockchain provides a distributed ledger technology that allows for the real-time exchange and verification of trial data across stakeholders while maintaining data integrity. Blockchain reduces data manipulation threats and assures regulatory compliance by streamlining data management, authentication, and consent procedures. This technology increases participant trust, shortens trial times, and lowers costs, revolutionising how clinical trials are done. As the desire for more accountability and data integrity develops, blockchain in clinical trials market is poised to revolutionise drug research and push patient care breakthroughs.

Blockchain In Clinical Trials Market Segmentation Analysis:

• Improved Data Transparency and Integrity Enhances the Blockchain in Clinical Trials Market Growth.

Improved data transparency and integrity are critical growth drivers in the blockchain in clinical trials market. Clinical trial data becomes visible, traceable, and tamper-proof thanks to blockchain's decentralised and immutable ledger architecture. Researchers, regulators, and patients may all safely access and verify data in real-time, encouraging confidence and collaboration. This increased transparency aids in the early detection and resolution of data anomalies, assuring the accuracy and dependability of trial outcomes. Furthermore, removing centralised data silos reduces the danger of data modification and unauthorised access, hence improving data integrity. As the requirement for robust data management and trust in clinical trials grows, so does the popularity of blockchain technology, driving market growth.

• Streamlined Data Management and Sharing in Blockchain in Clinical Trials Market.

A prominent growth element in the blockchain in clinical trials market is streamlined data management and sharing. The distributed ledger technology of blockchain streamlines data storage, organisation, and sharing among various stakeholders in a safe and efficient manner. Real-time updates on trial progress, patient data, and outcomes are available to researchers, healthcare providers, and regulators, allowing for seamless cooperation and decision-making. Data may be uploaded, updated, and audited in real-time, eliminating the need for manual record-keeping and unnecessary data entry. Blockchain technology improves the whole data management process by removing data silos and maintaining data integrity, shortening clinical trial deadlines and improving overall drug development and patient care efficiency.

• Reduction in Fraud and Data Manipulation Boosts the  Blockchain in Clinical Trials Market Size.

Reduced fraud and data tampering are critical growth drivers in the blockchain in clinical trials market. The decentralised and unchangeable nature of blockchain assures that data cannot be edited or erased once recorded, removing the danger of data tampering and unauthorised access. Each transaction on the blockchain is securely connected to prior entries, resulting in a data trail that is transparent and auditable. This improved data quality and openness discourages fraudulent practises and safeguards sensitive patient information. Blockchain technology fosters trust among stakeholders, including patients, researchers, and regulatory authorities, by reducing the possibility of data manipulation and ensuring the accuracy of clinical trial results, resulting in widespread adoption of this transformative technology in clinical trials.

Blockchain In Clinical Trials Market Geographical Outlook:

• North America is the Market Leader in the Blockchain in Clinical Trials Market.

North America was regarded as the market leader in the blockchain in clinical trials market. The popularity of this region may be linked to its well-established healthcare infrastructure, a strong emphasis on R&D, and the presence of numerous important pharmaceutical and biotechnology businesses. Furthermore, North America has been in the forefront of adopting and integrating cutting-edge technology such as blockchain into healthcare systems. The region's favourable regulatory framework, as well as alliances between research institutes and technology suppliers, have advanced the use of blockchain in clinical trials. However, market dynamics may have changed, in the top region in the blockchain in clinical trials market.

Blockchain In Clinical Trials Market Growth Drivers:

• Increased Patient Recruitment and Engagement in Blockchain in Clinical Trials Market.

Patient recruitment and engagement are important growth drivers in the blockchain in clinical trials market. Blockchain technology gives individuals more control over their health data and allows them to participate directly in clinical studies. Patients may safely exchange their health information with researchers and consent to participate in trials, which improves recruitment. Furthermore, the open and decentralised nature of blockchain increases patient confidence by offering a clear knowledge of how their data will be utilised and protecting data protection. Clinical trials can access a broader pool of varied participants with enhanced patient participation and empowerment, resulting in more representative and robust research outputs, eventually promoting improvements in medical treatments and cures.

Blockchain In Clinical Trials Market Company Products:

• Blockchain Infrastructure Solutions: Intel supplied hardware and software solutions for the development and deployment of blockchain networks. These infrastructure solutions sought to improve the performance, security, and scalability of clinical trial blockchain systems.
• Accenture myConcerto™: Accenture developed myConcerto™, a blockchain-enabled platform meant to improve clinical trial efficiency and transparency. The technology enabled stakeholders to share data in a safe and real-time manner, increasing cooperation and decision-making.
• IBM Clinical Development: The IBM Clinical Development platform, which combined blockchain technology to accelerate clinical trial data administration, was delivered by IBM Watson Health. The platform enabled secure and transparent data exchange among many parties, including researchers, sponsors, and regulatory bodies.
• Medidata Rave Clinical Cloud: Medidata Rave Clinical Cloud was a complete cloud-based platform that utilised blockchain technology for data management and security. The platform permitted the safe and tamper-proof gathering, processing, and storage of clinical trial data.

Blockchain In Clinical Trials Companies:

• Consensys Health
• Pfizer Inc.
• Encrypgen, Inc.
• Bitfury Group Limited
• Guardtime AS 

Blockchain In Clinical Trials Market Scope:

Report Metric	Details
Blockchain In Clinical Trials Market Size in 2025	USD 153.392 million
Blockchain In Clinical Trials Market Size in 2030	USD 428.191 million
Growth Rate	CAGR of 22.79%
Study Period	2020 to 2030
Historical Data	2020 to 2023
Base Year	2024
Forecast Period	2025 – 2030
Forecast Unit (Value)	USD Million
Segmentation	Type Of Blockchain Application End-User Geography
Geographical Segmentation	North America, South America, Europe, Middle East and Africa, Asia Pacific
List of Major Companies in the Blockchain In Clinical Trials Market	IBM Corporation Microsoft Corporation Oracle Corporation Accenture PLC Medidata Solutions, Inc.
Customization Scope	Free report customization with purchase

 

Segmentation:

• By Type Of Blockchain
  • Public Blockchain
  • Private Blockchain
  • Consortium Blockchain
  • Hybrid Blockchain   
• By Application
  • Patient Data Management
  • Supply Chain Management
  • Clinical Data Exchange And Sharing
  • Clinical Trial Recordkeeping
  • Informed Consent Management
  • Drug Traceability And Authenticity
  • Others                    
•  By End-User
  • Pharmaceutical Companies
  • Contract Research Organizations (Cros)
  • Research Institutes And Academic Centers
  • Healthcare Providers
  • Others              
•  By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Others
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain    
    • Others
  • Middle East and Africa
    • Saudi Arabia
    • UAE
    • Others
  • Asia Pacific
    • Japan
    • China
    • India
    • South Korea
    • Indonesia
    • Taiwan
    • Others

Our Best-Performing Industry Reports:

• Clinical Trial Market
• Clinical Trial Imaging Market
• Rare Diseases Clinical Trials Market

---

1. INTRODUCTION

1.1. Market Overview

1.2. Market Definition

1.3. Scope of the Study

1.4. Market Segmentation

1.5. Currency

1.6. Assumptions

1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY  

2.1. Research Data

2.2. Sources

2.3. Research Design

3. EXECUTIVE SUMMARY

3.1. Research Highlights

4. MARKET DYNAMICS

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.3.1. Bargaining Power of Suppliers

4.3.2. Bargaining Power of Buyers

4.3.3. Threat of New Entrants

4.3.4. Threat of Substitutes

4.3.5. Competitive Rivalry in the Industry

4.4. Industry Value Chain Analysis

5.  BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY TYPE OF BLOCKCHAIN

5.1. Introduction

5.2. PUBLIC BLOCKCHAIN

5.3. PRIVATE BLOCKCHAIN

5.4. CONSORTIUM BLOCKCHAIN

5.5. HYBRID BLOCKCHAIN   

6. BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY APPLICATION

6.1. Introduction

6.2. PATIENT DATA MANAGEMENT

6.3. SUPPLY CHAIN MANAGEMENT

6.4. CLINICAL DATA EXCHANGE AND SHARING

6.5. CLINICAL TRIAL RECORDKEEPING

6.6. INFORMED CONSENT MANAGEMENT

6.7. DRUG TRACEABILITY AND AUTHENTICITY

6.8. OTHERS                    

7.  BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY END-USER

7.1. Introduction

7.2. PHARMACEUTICAL COMPANIES

7.3. CONTRACT RESEARCH ORGANIZATIONS (CROS)

7.4. RESEARCH INSTITUTES AND ACADEMIC CENTERS

7.5. HEALTHCARE PROVIDERS

7.6. OTHERS              

7.7.  BLOCKCHAIN IN CLINICAL TRIALS MARKET, BY GEOGRAPHY

7.8. Introduction

7.9. North America

7.9.1. United States

7.9.2. Canada

7.9.3. Mexico

7.10. South America

7.10.1. Brazil

7.10.2. Argentina

7.10.3. Others

7.11. Europe

7.11.1. United Kingdom

7.11.2. Germany

7.11.3. France

7.11.4. Italy

7.11.5. Spain

7.11.6. Others

7.12. Middle East and Africa

7.12.1. Saudi Arabia

7.12.2. UAE

7.12.3. Others

7.13. Asia Pacific

7.13.1. Japan

7.13.2. China

7.13.3. India

7.13.4. South Korea

7.13.5. Indonesia 

7.13.6. Taiwan

7.13.7. Others

8. COMPETITIVE ENVIRONMENT AND ANALYSIS

8.1. Major Players and Strategy Analysis

8.2. Emerging Players and Market Lucrativeness

8.3. Mergers, Acquisitions, Agreements, and Collaborations

8.4. Vendor Competitiveness Matrix

9. COMPANY PROFILES

9.1. IBM CORPORATION

9.2. MICROSOFT CORPORATION

9.3. ORACLE CORPORATION

9.4. ACCENTURE PLC

9.5. MEDIDATA SOLUTIONS, INC. (NOW PART OF DASSAULT SYSTÈMES)

9.6. CONSENSYS HEALTH

9.7. PFIZER INC.

9.8. ENCRYPGEN, INC.

9.9. BITFURY GROUP LIMITED

9.10. GUARDTIME AS       

IBM Corporation

Microsoft Corporation

Oracle Corporation

Accenture PLC

Medidata Solutions, Inc. (Now Part Of Dassault Systèmes)

Consensys Health

Pfizer Inc.

Encrypgen, Inc.

Bitfury Group Limited

Guardtime AS